Table 4.
Clinicopathologic characteristics of sarcopenia patients. 1 In this study, underweight patients (BMI < 18.5 kg/m2) were excluded in analysis. 2 PSR was defined as relapse ≥6 months after completion of taxane- and platinum-based chemotherapy, whereas PRR as relapse <6 months. 3 In addition to PSR, the patients who completed taxane- and platinum-based chemotherapy and did not experience disease recurrence during at least six months of follow-up period were considered platinum-sensitive.
| Characteristics | FMR Low Group (n = 38, %) |
FMR High Group (n = 38, %) | p |
|---|---|---|---|
| Age, years | |||
| Mean ± SD | 54.0 ± 8.2 | 60.1 ± 10.6 | 0.006 |
| BMI 1, kg/m2 | |||
| Mean ± SD | 20.7 ± 1.5 | 23.6 ± 1.9 | <0.001 |
| Normal (18.5–22.9) | 33 (86.8) | 13 (34.2) | <0.001 |
| Overweight (23.0–24.9) | 5 (13.2) | 17 (44.7) | |
| Obesity (≥25.0) | 0 | 8 (21.1) | |
| Comorbidities | |||
| Hypertension | 7 (18.4) | 13 (34.2) | 0.118 |
| Diabetes | 3 (7.9) | 2 (5.3) | >0.999 |
| Dyslipidemia | 0 | 6 (15.8) | 0.025 |
| ASA score | 0.466 | ||
| 1 | 16 (42.1) | 16 (42.1) | |
| 2 | 20 (52.6) | 17 (44.7) | |
| 3 | 2 (5.3) | 5 (13.2) | |
| FIGO stage | 0.613 | ||
| III | 28 (73.7) | 26 (68.4) | |
| IV | 10 (26.3) | 12 (31.6) | |
| CA-125, IU/ml | |||
| Median (range) | 793.0 (13.0–24720.0) | 712.5 (5.1–7821.0) | 0.949 |
| Primary treatment strategy | 0.361 | ||
| PDS | 33 (86.8) | 30 (78.9) | |
| NAC | 5 (13.2) | 8 (21.1) | |
| Residual tumour after PDS/IDS | 0.533 | ||
| No gross | 23 (60.5) | 24 (63.2) | |
| <1 cm | 11 (28.9) | 7 (18.4) | |
| 1–2 cm | 2 (5.3) | 5 (13.2) | |
| ≥2 cm | 2 (5.3) | 2 (5.3) | |
| Regimen of first-line chemotherapy | 0.306 | ||
| Paclitaxel-Carboplatin | 36 (94.7) | 32 (84.2) | |
| Docetaxel-Carboplatin | 1 (2.6) | 4 (10.5) | |
| Paclitaxel-Carboplatin-Bevacizumab | 1 (2.6) | 2 (5.3) | |
| Main cycles of first-line chemotherapy | |||
| Median (range) | 6 (4–12) | 6 (4–12) | 0.374 |
| 4–6 | 28 (73.7) | 25 (65.8) | 0.725 |
| 7–9 | 8 (21.1) | 11 (28.9) | |
| 10–12 | 2 (5.3) | 2 (5.3) | |
| Recurrence | 30 (78.9) | 32 (842) | 0.554 |
| PSR 2 | 24 (63.2) | 24 (63.2) | 0.638 |
| PRR | 6 (15.8) | 8 (21.1) | |
| Platinum sensitivity | 0.554 | ||
| Platinum-sensitive 3 | 32 (84.2) | 30 (78.9) | |
| Platinum-resistant | 6 (15.8) | 8 (21.1) |
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; IDS, interval debulking surgery; NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery; PRR, platinum-resistant recurrence; PSR, platinum-sensitive recurrence; SD, standard deviation.